| |
| |
|
| Insider
Information: |
Szela Mary T |
| Relationship: |
|
| City: |
Abbott Park |
| State: |
IL |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
6 |
|
| Direct
Shares |
488,588 |
|
|
Indirect Shares
|
80 |
|
|
| Direct
Value |
$12,835,923 |
|
|
|
Indirect Value
|
$8,602 |
|
|
| Total
Shares |
488,668 |
|
|
| Total
Value |
$12,844,525 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
1
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
1
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
-1.0
|
| Percentage
Gain/Loss : |
0.0%
|
 -9.9%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Abbott Laboratories |
ABT |
Senior Vice President |
2011-12-14 |
119,342 |
2011-12-14 |
80 |
Premium* |
|
|
Receptos, Inc. |
RCPT |
Director |
2015-08-27 |
0 |
2015-05-28 |
0 |
Premium* |
|
|
Novelion Therapeutics Inc |
NVLN |
Chief Executive Office... |
2017-05-09 |
4,384 |
2017-05-09 |
0 |
Premium* |
|
|
Coherus Biosciences, Inc. |
CHRS |
Director |
2020-06-22 |
0 |
2020-06-22 |
0 |
Premium* |
|
|
Prometheus Biosciences, Inc. |
RXDX |
Director |
2023-06-16 |
0 |
2023-05-19 |
0 |
Premium* |
|
|
Trisalus Life Sciences Ord Shs |
TLSI |
|
2024-02-13 |
364,862 |
|
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| TLSI |
Trisalus Life Sciences Or... |
CEO AND PRESIDENT |
• • – |
2024-02-13 |
4 |
A |
$0.00 |
$0 |
D/D |
84,899 |
364,862 |
0 |
- |
|
| TLSI |
Trisalus Life Sciences Or... |
CEO and PresidentOfficer |
• • – |
2023-08-10 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
279,963 |
|
- |
|
| RXDX |
Prometheus Biosciences, I... |
Director |
– • – |
2023-06-16 |
4 |
D |
$0.00 |
$0 |
D/D |
(2,071) |
0 |
0 |
- |
|
| RXDX |
Prometheus Biosciences, I... |
Director |
– • – |
2023-05-19 |
4 |
A |
$0.00 |
$0 |
D/D |
2,071 |
2,071 |
0 |
- |
|
| CHRS |
Coherus Biosciences, Inc. |
Director |
– • – |
2020-06-22 |
4 |
S |
$17.58 |
$966,759 |
D/D |
(54,997) |
0 |
0 |
% |
|
| CHRS |
Coherus Biosciences, Inc. |
Director |
– • – |
2020-06-22 |
4 |
OE |
$2.50 |
$485,900 |
D/D |
54,997 |
54,997 |
0 |
- |
|
| NVLN |
Novelion Therapeutics Inc |
Chief Executive Officer |
• • – |
2017-05-09 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,632 |
6,632 |
0 |
- |
|
| NVLN |
Novelion Therapeutics Inc |
Chief Executive Officer |
• • – |
2017-05-09 |
4 |
D |
$9.42 |
$21,176 |
D/D |
(2,248) |
4,384 |
0 |
- |
|
| RCPT |
Receptos, Inc. |
Director |
– • – |
2015-08-27 |
4 |
D |
$0.00 |
$0 |
D/D |
(7,400) |
0 |
0 |
- |
|
| RCPT |
Receptos, Inc. |
Director |
– • – |
2015-05-28 |
4 |
A |
$0.00 |
$0 |
D/D |
7,400 |
7,400 |
0 |
- |
|
| ABT |
Abbott Laboratories |
Senior Vice President |
• – – |
2011-12-14 |
4 |
S |
$54.33 |
$2,893,724 |
D/D |
(53,201) |
119,342 |
0 |
- |
|
| ABT |
Abbott Laboratories |
Senior Vice President |
• – – |
2011-12-14 |
4 |
OE |
$53.63 |
$2,852,904 |
D/D |
53,201 |
172,543 |
0 |
- |
|
| ABT |
Abbott Laboratories |
Senior Vice President |
• – – |
2011-03-31 |
4 |
S |
$49.25 |
$786,054 |
D/D |
(15,960) |
119,342 |
0 |
- |
|
| ABT |
Abbott Laboratories |
Senior Vice President |
• – – |
2011-03-31 |
4 |
OE |
$48.12 |
$768,035 |
D/D |
15,960 |
135,302 |
0 |
- |
|
| ABT |
Abbott Laboratories |
Senior Vice President |
• – – |
2011-03-01 |
4 |
S |
$48.11 |
$830,862 |
D/D |
(17,267) |
119,342 |
0 |
- |
|
| ABT |
Abbott Laboratories |
Senior Vice President |
• – – |
2011-02-28 |
4 |
S |
$48.30 |
$96,026 |
D/D |
(1,988) |
136,609 |
0 |
- |
|
| ABT |
Abbott Laboratories |
Senior Vice President |
• – – |
2011-02-28 |
4 |
D |
$47.64 |
$469,016 |
D/D |
(9,845) |
138,597 |
0 |
- |
|
| ABT |
Abbott Laboratories |
Senior Vice President |
• – – |
2011-02-18 |
4 |
A |
$0.00 |
$0 |
D/D |
22,200 |
148,442 |
0 |
- |
|
| ABT |
Abbott Laboratories |
Senior Vice President |
• – – |
2010-11-23 |
4 |
GD |
$0.00 |
$0 |
D/D |
200 |
126,242 |
0 |
- |
|
| ABT |
Abbott Laboratories |
Senior Vice President |
• – – |
2010-08-27 |
4 |
D |
$49.50 |
$89,843 |
D/D |
(1,815) |
126,442 |
0 |
- |
|
| ABT |
Abbott Laboratories |
Senior Vice President |
• – – |
2010-03-01 |
4 |
S |
$54.35 |
$1,256,699 |
D/D |
(23,084) |
128,257 |
0 |
- |
|
| ABT |
Abbott Laboratories |
Senior Vice President |
• – – |
2010-02-26 |
4 |
D |
$54.12 |
$495,414 |
D/D |
(9,154) |
151,341 |
0 |
- |
|
| ABT |
Abbott Laboratories |
Senior Vice President |
• – – |
2010-02-19 |
4 |
A |
$0.00 |
$0 |
D/D |
40,600 |
160,495 |
0 |
- |
|
| ABT |
Abbott Laboratories |
Senior Vice President |
• – – |
2010-02-16 |
4 |
S |
$53.93 |
$80,897 |
D/D |
(1,500) |
119,895 |
0 |
- |
|
| ABT |
Abbott Laboratories |
Senior Vice President |
• – – |
2010-02-16 |
4 |
D |
$53.93 |
$240,636 |
D/D |
(4,462) |
121,395 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
